News & Views

Manage Immune-Related Adverse Events in Patients on Durvalumab

Durvalumab immunotherapy became a new standard of care for patients with stage III unresectable non-small cell lung cancer whose disease did not progress following two cycles of platinum-based chemoradiotherapy after its approval in February 2018, and in March 2020, its indication was expanded for use as first-line treatment in patients with extensive-stage small cell lung cancer as well. Key to keeping patients on immunotherapy treatment and giving them the best chance at long-term survival is effective management of immune-related adverse events.

August 11, 2020

Trending Topics

View All Topics

How Can ONS Support Members in Today’s Practice Changes?

ONS board of directors

How Can ONS Support Members in Today’s Practice Changes?

August 10, 2020

FDA Grants Accelerated Approval to Belantamab Mafodotin-Blmf for Multiple Myeloma

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Belantamab Mafodotin-Blmf for Multiple Myeloma

August 06, 2020

Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations

Treatment side effects

Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations

August 06, 2020

A Single Blood Test Could One Day Identify 10 Types of Cancer

Cancer research

A Single Blood Test Could One Day Identify 10 Types of Cancer

August 05, 2020

FDA Grants Accelerated Approval to Tafasitamab-Cxix for Diffuse Large B-Cell Lymphoma

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Tafasitamab-Cxix for Diffuse Large B-Cell Lymphoma

August 04, 2020

Not All Barriers to Care Are Created Equal

Cancer health disparities

Not All Barriers to Care Are Created Equal

August 04, 2020

FDA Approves Atezolizumab for BRAF V600 Unresectable or Metastatic Melanoma

U.S. Food and Drug Administration (FDA)

FDA Approves Atezolizumab for BRAF V600 Unresectable or Metastatic Melanoma

August 03, 2020

We Can’t Touch Each Other, But We Can Still Touch Lives

We Can’t Touch Each Other, But We Can Still Touch Lives

August 03, 2020

ONS Earns Awards for Publications and Periodicals

ONS Earns Awards for Publications and Periodicals

If You’re Trying to Be Productive, Stop Multitasking

Nurse self-care

If You’re Trying to Be Productive, Stop Multitasking

Antihistamines May Improve Survival From Malignant Melanoma

Antihistamines May Improve Survival From Malignant Melanoma

Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv

U.S. Food and Drug Administration (FDA)

Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv

$FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory MCL$

U.S. Food and Drug Administration (FDA)

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory MCL

Bertie A. Field, RN, MS

Meet Your ONS Leader: Bertie A. Field, RN, MS

Insulin Resistance May Explain Racial Disparity in Breast Cancer

Cancer research

Insulin Resistance May Explain Racial Disparity in Breast Cancer

The Case of the HPV-Positive Perk

Clinical practice

The Case of the HPV-Positive Perk

Ryan Conover, ONS director of information services

ONS Director Named Finalist for Pittsburgh’s CIO of the Year

What the Evidence Says for Use of Quigong in Patients With Cancer

Symptom management

What the Evidence Says for Use of Qigong in Patients With Cancer

The Case of the Thyroid Tradeoff

Clinical practice

The Case of the Thyroid Tradeoff

Opioid-Related Death Rates Are Increasing, But Less So in Cancer Survivors

Opioid-Related Death Rates Are Increasing, But Less So in Cancer Survivors

Telehealth Boom Opens New Roles for Oncology Nursing

Oncology nursing roles

Telehealth Boom Opens New Roles for Oncology Nursing

Managing Cancer-Related PTSD Starts With Acknowledgement

Patient empowerment

Managing Cancer-Related PTSD Starts With Acknowledgement

Pediatric Cancer Survivors Require Additional Care and Monitoring

Pediatric Cancer Survivors Require Additional Care and Monitoring

ONS Offers Companies the Oncology Nursing Society Seal of Approval™ to promote Oncology Nurse and Patient Support Materials

ONS Offers Companies the Oncology Nursing Society Seal of Approval™ to promote Oncology Nurse and Patient Support Materials

ONS Board Addresses Members About Racism and Disparities in Cancer Care

ONS Board Addresses Members About Racism and Disparities in Cancer Care

Myeloproliferative Neoplasm Symptoms, Diagnosis, Treatment, and Survivorship Recommendations

Myeloproliferative Neoplasm Symptoms, Diagnosis, Treatment, and Survivorship Recommendations

FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes

U.S. Food and Drug Administration (FDA)

FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes

Prostate Cancer Clinical Trials Don’t Reflect Racial Diversity—And It’s Getting Worse Over Time

Cancer research

Prostate Cancer Clinical Trials Don’t Reflect Racial Diversity—And It’s Getting Worse Over Time

Secondary Cancers in Pediatric Survivors

Secondary Cancers in Pediatric Survivors

How to Approach Medical Device Failures

Oncology nurse education

When Function Becomes Malfunction

Variants of Unknown Significance

Genetics & genomics

Help Patients Understand Genomic Variants of Unknown Significance

All Politics Is Local, and That’s Why You Should Get Involved in ONS Advocacy

Cancer healthcare advocacy

All Politics Is Local, and That’s Why You Should Get Involved in ONS Advocacy

FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment

Oncology drug research

FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment

Mental Well-Being Is a Focus of Primary Care Throughout Survivorship

Mental Well-Being Is a Focus of Primary Care Throughout Survivorship

Antibody-Drug Conjugates Join the Best of Two Worlds Into One New Treatment

Cancer research

Antibody-Drug Conjugates Join the Best of Two Worlds Into One New Treatment

FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer

U.S. Food and Drug Administration (FDA)

FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer

FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf for HER2-Positive Breast Cancer

Oncology drug research

FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf for HER2-Positive Breast Cancer

Develop Your Individual Cancer Screening Plan

Cancer screening

Develop Your Individual Cancer Screening Plan

FDA Approves Pembrolizumab for Treatment of Cutaneous Squamous Cell Carcinoma

Oncology drug research

FDA Approves Pembrolizumab for Treatment of Cutaneous Squamous Cell Carcinoma

How to Practice Self-Care During Times of Uncertainty

Nurse self-care

How to Practice Self-Care During Times of Uncertainty

Cancer Consortium Report Reveals High Mortality Rates in Patients With COVID-19 and Cancer

Cancer Consortium Report Reveals High Mortality Rates in Patients With COVID-19 and Cancer

Nurses Can Provide Safe Spaces for LGBTQ Patients With Cancer

Patient advocacy

Nurses Can Provide Safe Spaces for LGBTQ Patients With Cancer

$FDA Approves Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

Oncology drug research

FDA Approves Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

HIV-Positive Patients With Cancer Need to Be Included in Clinical Drug Trials

U.S. Food and Drug Administration (FDA)

HIV-Positive Patients With Cancer Need to Be Included in Clinical Drug Trials

Meet Your ONS Leader: Kristin Ferguson, DNP, RN, OCN®

Meet Your ONS Leader: Kristin Ferguson, DNP, RN, OCN®

FDA Grants Accelerated Approval to Tazemetostat for Follicular Lymphoma

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Tazemetostat for Follicular Lymphoma

Polypharmacy Before Cancer Is Predictive of Post-Treatment Hospitalization

Polypharmacy Before Cancer Is Predictive of Post-Treatment Hospitalization

FDA Approves Pembrolizumab for Patients With TMB-H Solid Tumors

U.S. Food and Drug Administration (FDA)

FDA Approves Pembrolizumab for Patients With TMB-H Solid Tumors

Misconceptions About Radioactive Targeted Therapies

Genetics & genomics

An Oncology Nurse’s Primer on Genomics and Biomarker Terminology

Back to Top ▲